Sign inJoin waitlistJoin the waitlist

Nadine Tung

Hematology and Oncology Research Investigator · Beth Israel Deaconess Medical Center

Credentials: · · ·

History

Beth Israel Deaconess Medical Center
Present

Hematology and Medical Oncology
Beth Israel Deaconess Medical Center
1987–1990
Internal Medicine
Beth Israel Deaconess Medical Center
1984–1987
Harvard Medical School
1980–1984

Research

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
New England Journal of Medicine · 2017 · 2,618 citations
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality
JAMA · 2010 · 1,140 citations
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Clinical Cancer Research · 2016 · 899 citations

Judy Garber
101 papers
Beth Karlan
86 papers
Olufunmilayo Olopade
81 papers
Susan Domchek
76 papers
Jeffrey Weitzel
68 papers
HL
Henry Lynch
63 papers
Claudine Isaacs
62 papers
KO
Kenneth Offit
50 papers
Katherine Nathanson
47 papers
Mary Daly
40 papers
MR
Mark Robson
39 papers
Banu Arun
34 papers

Clinical trials

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Principal investigator · Active not recruiting · Phase 2
ECOG-ACRIN Cancer Research Group
2020–2038
Olaparib In Metastatic Breast Cancer
Principal investigator · Active not recruiting · Phase 2
Beth Israel Deaconess Medical Center
2018–2026
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer
Principal investigator · Completed
Ambry Genetics
2016–2020
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Principal investigator · Completed · Phase 2
Beth Israel Deaconess Medical Center
2012–2025